For example, ATT using multiple T cell Receptors (TCRs), which recognize HLA-A*02:01+ spliced epitopes carrying KRAS mutations, could treat around 30% of pancreatic adenocarcinoma patients and a large portion of colorectal carcinoma patients. Here, KRAS is linked to colorectal carcinoma.